Promising ADC Pipeline | Elevation Oncology's lead candidate EO-3021 shows best-in-class efficacy for gastric cancers, with a 43% objective response rate in Claudin-selected patients |
Safety Advantage | EO-3021's favorable safety profile, particularly the absence of significant hematological adverse events, positions it well for potential combination therapies |
Strategic Combinations | Explore Elevation's innovative approach to combining EO-3021 with existing treatments, potentially expanding its market reach in first and second-line settings |
Financial Outlook | With a $111M cash balance and analyst price targets ranging from $6 to $7, Elevation Oncology is positioned to fund operations through key clinical milestones into 2026 |
Metrics to compare | ELEV | Peers Peers - average of corresponding metrics from companies closely matching ELEV: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipELEVPeersSector |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |